2241732-30-7

2241732-30-7 structure

Name	BTK-030

Description	BTK-030 is a novel BTK inhibitor.
Related Catalog	Research Areas >> Inflammation/Immunology Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk
Target	IC50: Bruton kinase (BTK)[1]
In Vivo	BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33[1]. Animal Model: DBA/1J mice injected with collagen as a CIA model[1] Dosage: 30 mg/kg Administration: oral gavage; 21 days; once daily Result: Decreased arthritis scores significantly when it compares to control group.
References	[1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525

Molecular Formula	C₂₅H₂₃N₅O₃
Molecular Weight	441.491